<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00026208</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-13081</org_study_id>
    <secondary_id>LYMHD0002</secondary_id>
    <nct_id>NCT00026208</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma</brief_title>
  <official_title>Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining chemotherapy with radiation therapy may kill more tumor cells.

      PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together
      with low-dose radiation therapy works in treating patients with stage I or stage IIA
      Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the freedom from progression in patients with stage I or IIA Hodgkin's lymphoma
           with a favorable prognosis treated with &quot;Stanford V-C&quot; chemotherapy comprising
           cyclophosphamide, doxorubicin, vinblastine, prednisone, vincristine, bleomycin, and
           etoposide with low-dose radiotherapy (RT).

        -  Minimize the early and late effects of treatment in these patients by avoiding staging
           laparotomy and its consequences, limiting cumulative doses of chemotherapy, and reducing
           the dose of RT to moderately bulky sites of disease.

        -  Assess early and late treatment-related toxicity, freedom from second disease
           progression, and overall survival at 5 and 10 years in patients treated with this
           regimen.

      Participants receive Stanford V-C chemotherapy comprising cyclophosphamide IV over 30 to 60
      minutes weekly on weeks 1 and 5; doxorubicin IV and vinblastine IV over 5 minutes once weekly
      on weeks 1, 3, 5, and 7; oral prednisone every other day on weeks 1 to 8; vincristine IV, and
      bleomycin IV over 5 minutes once weekly on weeks 2, 4, 6, and 8; and etoposide IV over 60
      minutes on days 1 and 2 of weeks 3 and 7. Prior to protocol amendment, participants were
      assigned to treatment on the basis of tumor size (&lt; 5 cm vs 5 to 10 cm), with only the
      participants with larger tumors receiving RT. Beginning 2 to 3 weeks after completion of
      chemotherapy, participants in the +RT group will receive low-dose radiotherapy 5 days a week
      for approximately 3 weeks. Subsequent to amendment, all participants received RT.

      Participants are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">February 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 26, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with tumors 5 to 10 cm were to be assigned to concurrent radiotherapy, and participants with tumors less than 5 cm were initially planned to not receive radiotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-free survival was assessed for 3 years from the completion of treatment. Progression-free survival was considered to mean the proportion of patients (percentage) still alive without disease recurrence or progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Complete Response</measure>
    <time_frame>5 weeks</time_frame>
    <description>The frequency of complete response (CR) is reported as the number (proportion) of subjects in complete response, as assessed during weeks 4 to 5 of chemotherapy. Per protocol, CR is defined as &quot;complete regression of all palpable and radiographic demonstrable disease&quot; by computed tomography (CT) scan or positron emission tomography-CT (PET-CT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment-related Toxicity</measure>
    <time_frame>Within 30 days of treatment</time_frame>
    <description>Early treatment-related toxicity was assessed as the number of treatment-related, non-serious adverse events that occurred during treatment or within 30 days of the completion of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Treatment-related Toxicity</measure>
    <time_frame>16 years</time_frame>
    <description>Late treatment-related toxicity was assessed as the overall number of late-appearing toxicities (ie, related adverse events, after treatment completion) including but not limited to diagnosis of a 2nd cancer; hypothyroidism; infertility; pulmonary toxicity; or cardiac toxicity, at up to 16 years from date of diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Hodgkin's Disease Progression</measure>
    <time_frame>16 years</time_frame>
    <description>Second Hodgkin's disease progression is reported as the number of participants experiencing 2 instances of progression of the underlying Hodgkin's disease, assessed at up to 16 years from date of diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>16 years</time_frame>
    <description>Overall survival was assessed at up to 16 years from date of diagnosis, and reported as the median years of survival with standard deviation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Lymphoma, Hodgkin Disease</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma: Hodgkin</condition>
  <arm_group>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Sanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Radiotherapy = 20 Gy modified involved field radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Sanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Vinblastine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>LCR</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincristin</other_name>
    <other_name>Vincristina</other_name>
    <other_name>Vincristinum</other_name>
    <other_name>22-Oxovincaleukoblastin</other_name>
    <other_name>22-Oxovincaleukoblastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>650 mg/m², on week 1 and 5</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphamid</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester</other_name>
    <other_name>2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide</other_name>
    <other_name>N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>25 mg/m², on week 1, 3, 5, 7</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Doxorubicinum</other_name>
    <other_name>Doxorubicine</other_name>
    <other_name>Rubex</other_name>
    <other_name>Hydroxydaunomycin HCl</other_name>
    <other_name>Hydroxydoxorubicin HCl</other_name>
    <other_name>Hydroxydaunorubicin</other_name>
    <other_name>14-hydroxydaunomycin</other_name>
    <other_name>14-hydroxydaunorubicine</other_name>
    <other_name>(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside</other_name>
    <other_name>(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Dehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Orasone</other_name>
    <other_name>Prednicot</other_name>
    <other_name>predniSONE Intensol</other_name>
    <other_name>Rayos</other_name>
    <other_name>Sterapred</other_name>
    <other_name>Prednisona</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>1,2-Dehydrocortisone</other_name>
    <other_name>1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione</other_name>
    <other_name>17,21-Dihydroxypregna-1,4-diene-3,11,20-trione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>5 u/m² intravenously (IV) on week 2, 4, 6, 8</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Bleomycin A2</other_name>
    <other_name>Bleomycine</other_name>
    <other_name>Bleocin</other_name>
    <other_name>Bleomicin</other_name>
    <other_name>Bleomicina</other_name>
    <other_name>Bleomycinum</other_name>
    <other_name>BLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
    <arm_group_label>Stanford V-C only</arm_group_label>
    <other_name>Toposar</other_name>
    <other_name>Etopophos</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP-16</other_name>
    <other_name>Etoposido</other_name>
    <other_name>Etoposidum</other_name>
    <other_name>trans-Etoposide</other_name>
    <other_name>4-demethylepipodophyllotoxin β-D-ethylideneglucoside</other_name>
    <other_name>4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)</other_name>
    <other_name>9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low-dose radiotherapy (RT)</intervention_name>
    <description>20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
    <arm_group_label>Stanford V-C + Low-dose Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes

               -  Nodular sclerosis

               -  Mixed cellularity

               -  Classical, not otherwise specified

          -  Age ≥ 18 years and ≤ 70 years

          -  Granulocytes ≥ 2 x 10e6/µL

          -  Platelets ≥ 150 x 10e6/µL

          -  Bilirubin ≤ 2.5 mg/dL

          -  Serum creatinine ≤ 2 mg/dL

          -  Patients &gt; 50 years or those with a history of cardiac disease should have an ejection
             fraction ≥ 50%

          -  All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment

          -  Pathologic material reviewed at Stanford University

          -  Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the
             Hodgkin's Disease Staging Conference

          -  Written informed consent

        EXCLUSION CRITERIA:

          -  Lymphocytic predominance Hodgkin's disease

          -  Prior treatment for Hodgkin's disease

          -  Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter
             on a standing posteroanterior chest x-ray

          -  Any lymph node mass &gt; 10 cm in greatest trans-axial diameter

          -  Two or more extranodal sites of disease

          -  Constitutional (B) symptoms present at diagnosis

          -  Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of
             the skin)

          -  Any medical contraindication to the planned treatment, including:

               -  Pregnant

               -  Positive antibody test for the human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjana H Advani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>March 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ranjana Advani</investigator_full_name>
    <investigator_title>Saul A. Rosenberg, MD, Professor of Lymphoma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stanford V-C + Low-dose Radiotherapy</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
        </group>
        <group group_id="P2">
          <title>Stanford V-C Only</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Complications of auto accident</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Prior to amendment, participants with tumor size &lt; 5 cm received Stanford V-C only. Subsequent to amendment, all participants received Stanford V-C + low-dose radiotherapy (RT)</population>
      <group_list>
        <group group_id="B1">
          <title>Stanford V-C + Low-dose Radiotherapy</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
        </group>
        <group group_id="B2">
          <title>Stanford V-C Only</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival was assessed for 3 years from the completion of treatment. Progression-free survival was considered to mean the proportion of patients (percentage) still alive without disease recurrence or progression.</description>
        <time_frame>up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival was assessed for 3 years from the completion of treatment. Progression-free survival was considered to mean the proportion of patients (percentage) still alive without disease recurrence or progression.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Complete Response</title>
        <description>The frequency of complete response (CR) is reported as the number (proportion) of subjects in complete response, as assessed during weeks 4 to 5 of chemotherapy. Per protocol, CR is defined as &quot;complete regression of all palpable and radiographic demonstrable disease&quot; by computed tomography (CT) scan or positron emission tomography-CT (PET-CT).</description>
        <time_frame>5 weeks</time_frame>
        <population>Participants, for whom a PET-CT scan was not conducted in week 4 to 5 of treatment, were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Complete Response</title>
          <description>The frequency of complete response (CR) is reported as the number (proportion) of subjects in complete response, as assessed during weeks 4 to 5 of chemotherapy. Per protocol, CR is defined as &quot;complete regression of all palpable and radiographic demonstrable disease&quot; by computed tomography (CT) scan or positron emission tomography-CT (PET-CT).</description>
          <population>Participants, for whom a PET-CT scan was not conducted in week 4 to 5 of treatment, were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment-related Toxicity</title>
        <description>Early treatment-related toxicity was assessed as the number of treatment-related, non-serious adverse events that occurred during treatment or within 30 days of the completion of treatment.</description>
        <time_frame>Within 30 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment-related Toxicity</title>
          <description>Early treatment-related toxicity was assessed as the number of treatment-related, non-serious adverse events that occurred during treatment or within 30 days of the completion of treatment.</description>
          <units>treatment-related adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Treatment-related Toxicity</title>
        <description>Late treatment-related toxicity was assessed as the overall number of late-appearing toxicities (ie, related adverse events, after treatment completion) including but not limited to diagnosis of a 2nd cancer; hypothyroidism; infertility; pulmonary toxicity; or cardiac toxicity, at up to 16 years from date of diagnosis.</description>
        <time_frame>16 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Late Treatment-related Toxicity</title>
          <description>Late treatment-related toxicity was assessed as the overall number of late-appearing toxicities (ie, related adverse events, after treatment completion) including but not limited to diagnosis of a 2nd cancer; hypothyroidism; infertility; pulmonary toxicity; or cardiac toxicity, at up to 16 years from date of diagnosis.</description>
          <units>treatment-related adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Second Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Second Hodgkin's Disease Progression</title>
        <description>Second Hodgkin's disease progression is reported as the number of participants experiencing 2 instances of progression of the underlying Hodgkin's disease, assessed at up to 16 years from date of diagnosis.</description>
        <time_frame>16 years</time_frame>
        <population>Data to confirm Hodgkin's disease 2nd progression was not available for some participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Second Hodgkin's Disease Progression</title>
          <description>Second Hodgkin's disease progression is reported as the number of participants experiencing 2 instances of progression of the underlying Hodgkin's disease, assessed at up to 16 years from date of diagnosis.</description>
          <population>Data to confirm Hodgkin's disease 2nd progression was not available for some participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was assessed at up to 16 years from date of diagnosis, and reported as the median years of survival with standard deviation.</description>
        <time_frame>16 years</time_frame>
        <population>Does not include those participants that were lost-to-follow-up or whose treatment was significantly modified due to accidental injury.</population>
        <group_list>
          <group group_id="O1">
            <title>Stanford V-C + Low-dose Radiotherapy</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Stanford V-C Only</title>
            <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival was assessed at up to 16 years from date of diagnosis, and reported as the median years of survival with standard deviation.</description>
          <population>Does not include those participants that were lost-to-follow-up or whose treatment was significantly modified due to accidental injury.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="2.8"/>
                    <measurement group_id="O2" value="13.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stanford V-C + Low-dose Radiotherapy</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
&quot;Low-dose radiotherapy (RT)&quot; = 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.</description>
        </group>
        <group group_id="E2">
          <title>Stanford V-C Only</title>
          <description>&quot;Stanford V-C&quot; = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
Vincristine: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Cyclophosphamide: 650 mg/m², on week 1 and 5
Doxorubicin: 25 mg/m², on week 1, 3, 5, 7
Prednisone: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² mg every other day during last 2 weeks of chemotherapy
Bleomycin: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Etoposide: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Crush injury, automobile accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection with grade 3 ANC grade 2 ATT (no hospitalization)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metallic Taste in Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mild Oral Sensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral Toxicity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gas pains</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/Malaise</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tenderness at the PICC site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Discomfort, burning &amp; increased sensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PICC line removed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chest soreness and tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, inflammation of left arm above IV site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aches and pains</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, axilla &amp; breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sorness in upper and lower extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Substernal chest pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, jaw</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, hips and legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Joint pains, back and hips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ache and heaviness in left arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, right groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Generalized achiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, related to PICC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="101" subjects_affected="55" subjects_at_risk="72"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Secondary to automobile accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, bilateral arms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, bone and muscle</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, lower back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Arthralgias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncopal episode with brief loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Altered taste sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood spotting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gross hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vein Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica C Lam, BS</name_or_title>
      <organization>Stanford Univeristy Medical Center</organization>
      <phone>650-723-0437</phone>
      <email>jclam11@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

